Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Towards the development of novel Trypanosoma brucei RNA editing ligase 1 inhibitors.

Durrant JD, McCammon JA.

BMC Pharmacol. 2011 Aug 30;11:9. doi: 10.1186/1471-2210-11-9.

2.

High resolution crystal structure of a key editosome enzyme from Trypanosoma brucei: RNA editing ligase 1.

Deng J, Schnaufer A, Salavati R, Stuart KD, Hol WG.

J Mol Biol. 2004 Oct 22;343(3):601-13.

PMID:
15465048
3.

Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei.

Amaro RE, Schnaufer A, Interthal H, Hol W, Stuart KD, McCammon JA.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17278-83. doi: 10.1073/pnas.0805820105.

4.

Novel naphthalene-based inhibitors of Trypanosoma brucei RNA editing ligase 1.

Durrant JD, Hall L, Swift RV, Landon M, Schnaufer A, Amaro RE.

PLoS Negl Trop Dis. 2010 Aug 24;4(8):e803. doi: 10.1371/journal.pntd.0000803.

5.

Designing novel inhibitors of Trypanosoma brucei.

Demir O, Amaro RE.

Methods Mol Biol. 2013;993:231-43. doi: 10.1007/978-1-62703-342-8_15.

PMID:
23568474
6.

Mutational analysis of Trypanosoma brucei RNA editing ligase reveals regions critical for interaction with KREPA2.

Mehta V, Sen R, Moshiri H, Salavati R.

PLoS One. 2015 Mar 19;10(3):e0120844. doi: 10.1371/journal.pone.0120844.

7.

Computer-aided discovery of Trypanosoma brucei RNA-editing terminal uridylyl transferase 2 inhibitors.

Demir O, Labaied M, Merritt C, Stuart K, Amaro RE.

Chem Biol Drug Des. 2014 Aug;84(2):131-9. doi: 10.1111/cbdd.12302.

8.

The structure of the C-terminal domain of the largest editosome interaction protein and its role in promoting RNA binding by RNA-editing ligase L2.

Park YJ, Budiarto T, Wu M, Pardon E, Steyaert J, Hol WG.

Nucleic Acids Res. 2012 Aug;40(14):6966-77. doi: 10.1093/nar/gks369.

10.

Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening.

Pedró-Rosa L, Buckner FS, Ranade RM, Eberhart C, Madoux F, Gillespie JR, Koh CY, Brown S, Lohse J, Verlinde CL, Fan E, Bannister T, Scampavia L, Hol WG, Spicer T, Hodder P.

J Biomol Screen. 2015 Jan;20(1):122-30. doi: 10.1177/1087057114548832. Erratum in: J Biomol Screen. 2016 Jul;21(6):653.

11.

Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode.

Spinks D, Smith V, Thompson S, Robinson DA, Luksch T, Smith A, Torrie LS, McElroy S, Stojanovski L, Norval S, Collie IT, Hallyburton I, Rao B, Brand S, Brenk R, Frearson JA, Read KD, Wyatt PG, Gilbert IH.

ChemMedChem. 2015 Nov;10(11):1821-36. doi: 10.1002/cmdc.201500301.

12.

Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness.

Koh CY, Kim JE, Wetzel AB, de van der Schueren WJ, Shibata S, Ranade RM, Liu J, Zhang Z, Gillespie JR, Buckner FS, Verlinde CL, Fan E, Hol WG.

PLoS Negl Trop Dis. 2014 Apr 17;8(4):e2775. doi: 10.1371/journal.pntd.0002775.

13.

Functional complementation of Trypanosoma brucei RNA in vitro editing with recombinant RNA ligase.

Gao G, Simpson AM, Kang X, Rogers K, Nebohacova M, Li F, Simpson L.

Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4712-7.

14.

A novel high-throughput activity assay for the Trypanosoma brucei editosome enzyme REL1 and other RNA ligases.

Zimmermann S, Hall L, Riley S, Sørensen J, Amaro RE, Schnaufer A.

Nucleic Acids Res. 2016 Feb 18;44(3):e24. doi: 10.1093/nar/gkv938.

15.

Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug design.

Pizarro JC, Hills T, Senisterra G, Wernimont AK, Mackenzie C, Norcross NR, Ferguson MA, Wyatt PG, Gilbert IH, Hui R.

PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2492. doi: 10.1371/journal.pntd.0002492.

16.

The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis.

Urich R, Grimaldi R, Luksch T, Frearson JA, Brenk R, Wyatt PG.

J Med Chem. 2014 Sep 25;57(18):7536-49. doi: 10.1021/jm500239b.

17.

Discovery of N-(4-sulfamoylphenyl)thioureas as Trypanosoma brucei leucyl-tRNA synthetase inhibitors.

Zhang F, Du J, Wang Q, Hu Q, Zhang J, Ding D, Zhao Y, Yang F, Wang E, Zhou H.

Org Biomol Chem. 2013 Aug 28;11(32):5310-24. doi: 10.1039/c3ob40236c.

PMID:
23842857
18.

Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.

Tulloch LB, Martini VP, Iulek J, Huggan JK, Lee JH, Gibson CL, Smith TK, Suckling CJ, Hunter WN.

J Med Chem. 2010 Jan 14;53(1):221-9. doi: 10.1021/jm901059x.

19.

Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.

Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, Buckner FS, Gelb MH, Domostoj MM, Wells SJ, Scheer A, Wells TN, Van Voorhis WC.

Antimicrob Agents Chemother. 2008 Oct;52(10):3710-7. doi: 10.1128/AAC.00364-08.

20.

Distinct functions of two RNA ligases in active Trypanosoma brucei RNA editing complexes.

Cruz-Reyes J, Zhelonkina AG, Huang CE, Sollner-Webb B.

Mol Cell Biol. 2002 Jul;22(13):4652-60.

Supplemental Content

Support Center